Please ensure Javascript is enabled for purposes of website accessibility

Why Ampio Pharmaceuticals Stock Is Jumping Today

By Keith Speights - Mar 4, 2021 at 12:33PM

You’re reading a free article with opinions that may differ from The Motley Fool’s Premium Investing Services. Become a Motley Fool member today to get instant access to our top analyst recommendations, in-depth research, investing resources, and more. Learn More

Investors liked what they heard in the company's Q4 update.

What happened

Shares of Ampio Pharmaceuticals (AMPE -9.95%) were jumping 8.4% as of 11:51 a.m. EST on Thursday. The nice gain came after the company provided its fourth-quarter update following the market close on Wednesday. 

So what

Investors probably didn't care all that much about Ampio's Q4 results. (For what it's worth, the drugmaker posted a net loss of $15.9 million, or $0.09 per diluted share, with no revenue.) Instead, the primary catalyst for the biotech stock was that Ampio provided additional clarity on where it stands with the U.S. Food and Drug Administration (FDA) on a couple of fronts.

Man wearing a coat and tie holding yellow blocks with red letters on the blocks spelling FDA

Image source: Getty Images.

Ampio CEO Michael Macaluso said that the FDA wants the company to conduct two phase 2 studies of its lead product Ampion before the agency will consider Emergency Use Authorization (EUA) for the drug in treating COVID-19. One of those studies is for the intravenous version of Ampion and the other for the inhaled version.

Macaluso also stated that Ampio has handed over a detailed proposal to the FDA for the continuation of its late-stage study of Ampion in treating osteoarthritis of the knee. This study has been paused due to the COVID-19 pandemic. Ampio seeks to analyze existing data for patients who had completed the 12-week regimen for use in filing for approval.

Now what

The FDA hasn't made a final decision on how Ampion can proceed with its late-stage study. Until the agency makes the call, the study will remain paused.

Invest Smarter with The Motley Fool

Join Over 1 Million Premium Members Receiving…

  • New Stock Picks Each Month
  • Detailed Analysis of Companies
  • Model Portfolios
  • Live Streaming During Market Hours
  • And Much More
Get Started Now

Stocks Mentioned

Ampio Pharmaceuticals, Inc. Stock Quote
Ampio Pharmaceuticals, Inc.
$0.18 (-9.95%) $0.02

*Average returns of all recommendations since inception. Cost basis and return based on previous market day close.

Related Articles

Motley Fool Returns

Motley Fool Stock Advisor

Market-beating stocks from our award-winning service.

Stock Advisor Returns
S&P 500 Returns

Calculated by average return of all stock recommendations since inception of the Stock Advisor service in February of 2002. Returns as of 05/18/2022.

Discounted offers are only available to new members. Stock Advisor list price is $199 per year.

Premium Investing Services

Invest better with The Motley Fool. Get stock recommendations, portfolio guidance, and more from The Motley Fool's premium services.